| EpCAM is overexpressed in gastric cancer and its downregulation suppresses proliferation of gastric cancer. | gastric, |
| The EpCAM was a potential oncogene and contributed to the growth of gastric cancer. The data first provided compelling evidence of potential value of EpCAM in the therapy of gastric cancer in clinic. | gastric, |
| EpCAM has oncogenic potential and is activated by release of its intracellular domain, which can signal into the cell nucleus by engagement of elements of the wnt pathway. | None |
| Activation of EpCAM_s cleavage and oncogenic capacity is dependent on cellular interaction | None |
| EpCAM overexpression reduced PTEN expression and increased the level of AKT, mTOR, p70S6K and 4EBP1 phosphorylation and an AKT inhibitor and rapamycin blocked the effect of EpCAM on NPC cell invasion and stem-like phenotypes, and siRNA targeting PTEN rescued the oncogenic activities in EpCAM knockdown NPC cells. | None |